| Literature DB >> 34193304 |
Alemu Degu Ayele1, Bekalu Getnet Kassa2, Fentahun Yenealem Beyene3, Dagne Addisu Sewyew2, Gedefaye Nibret Mihretie2.
Abstract
BACKGROUND: Dual contraceptive is the use of a barrier like condom along with any modern contraceptive methods which has double significance for the prevention STI including HIV and unintended pregnancy. The prevalence and determinants of dual contraceptive utilization described by different studies were highly inconsistent in Ethiopia. Therefore, this systematic review and meta-analysis aimed to estimate the pooled prevalence and determinants of dual contraceptive utilization among HIV positive women in Ethiopia.Entities:
Keywords: Determinants; Dual contraceptive; Ethiopia; Meta-analysis; Systematic review; Utilization
Year: 2021 PMID: 34193304 PMCID: PMC8247245 DOI: 10.1186/s40834-021-00161-w
Source DB: PubMed Journal: Contracept Reprod Med ISSN: 2055-7426
Fig. 1Flow chart describing the selection of studies for the systematic review and meta-analysis of prevalence and determinants of modern contraceptive utilization among HIV positive women’s in Ethiopia, 2020
Characteristics of included primary studies showing dual contraceptive utilization and determinants among HIV positive women in Ethiopia, systematic review and meta-analysis, 2020
| Authors | Year of publication | Region | Study design | Sample size | Response rate (%) | Prevalence (95%CI) | Quality |
|---|---|---|---|---|---|---|---|
| Abay et al. [ | 2020 | Amhara | C/S | 563 | 98 | 28.8 (26.83,30.77) | Low risk |
| Reta et al. [ | 2019 | Amhara | C/S | 619 | 98.25 | 13.2 (11.72,14.68) | Low risk |
| Kebede et al. [ | 2015 | Amhara | C/S | 420 | 99.04 | 26.7 (24.77,28.63) | Low risk |
| Egzeabher et al. [ | 2015 | Amhara | C/S | 335 | 98.5 | 19 (17.29,20.71) | Low risk |
| Tewabe et al. | 2018 | Amhara | C/S | 308 | 100 | 26 (24.09,27.91) | Low risk |
| Asfaw et al. [ | 2014 | AA | C/S | 1418 | 100 | 18 (16.32,19.68) | Low risk |
| Demissie et al. [ | 2015 | Oromia | C/S | 357 | 100 | 32 (29.96,34.04) | Low risk |
| Sufa et al. [ | 2013 | Oromia | C/S | 461 | 98.9 | 22.4 (20.58,24.22) | Low risk |
| Polis et al. [ | 2014 | Oromia | C/S | 395 | 93.2 | 17 (15.36,18.64) | Low risk |
| Dereje et al. [ | 2019 | Oromia | C/S | 323 | 94.1 | 59.5 (57.36,61.64) | Low risk |
| Feyissa et al. [ | 2020 | Oromia | C/S | 360 | 100 | 17 (15.36,18.64) | Low risk |
| Tesfaye et al. [ | 2014 | Oromia | C/S | 403 | 99.5 | 31.9 (29.86,33.94) | Low risk |
| Gebrehiwot et al [ | 2017 | Tigray | C/S | 331 | 97.9 | 15.7 (14.11,17.29) | Low risk |
| Kalayu [ | 2019 | Tigray | C/S | 632 | 100 | 45.2 (43.03,47.37) | Low risk |
| Melaku et al. [ | 2014 | Tigray | C/S | 964 | 100 | 14 (12.48,15.52) | Low risk |
| Berhane.et al. [ | 2013 | Tigray | C/S | 364 | 99.2 | 21.6 (19.80,23.40) | Low risk |
| Assefa et al. [ | 2014 | Benishangul | C/S | 404 | 100 | 40.9 (38.75,43.06) | Low risk |
| Markos et al. [ | 2019 | SNNP | C/S | 269 | 95.9 | 28.3 (26.34,30.26) | Low risk |
| Meseret et al. [ | 2015 | SNNP | C/S | 243 | 98.78 | 19.8 (18.06,21.54) | Low risk |
AA Addis Ababa, SNNP Southern Nations Nationalities Peoples, C/S Cross-sectional
Fig. 2Forest plot of the pooled prevalence of dual contraceptive use among HIV positive women in Ethiopia, 2020
Fig. 3a Funnel plot to test publication bias of 19 studies. b Result of trim and fill analysis for adjusting publication bias of the 25 studies
Sensitivity analysis of the prevalence of dual contraceptive utilization among HIV positive women in Ethiopia 2020
| Study omitted | Prevalence (%) | 95%CI |
|---|---|---|
| Abay et al. (2020) [ | 25.99 | 20.82–31.16 |
| Reta et al. (2019) [ | 26.86 | 21.79–31.95 |
| Kebede et al. (2015) [ | 26.11 | 20.92–31.30 |
| Egzeabher et al. (2015) [ | 26.54 | 21.34–31.74 |
| Tewabe et al. (2018) | 26.15 | 20.95–31.35 |
| Asfaw et al. (2014) [ | 26.59 | 21.40–31.78 |
| Demissie et al. (2015) [ | 25.81 | 20.69–30.93 |
| Sufa et al. (2013) [ | 26.35 | 21.13–31.56 |
| Polis et al. (2014) [ | 26.65 | 21.47–31.82 |
| Dereje (2019) [ | 24.28 | 20.37–28.18 |
| Feyissa et al. (2020) [ | 26.65 | 21.47–31.82 |
| Tesfaye et al. (2014) [ | 25.82 | 20.69–30.94 |
| Gebrehiwot et al. (2017) [ | 26.72 | 21.57–31.87 |
| Kalayu (2019) [ | 25.08 | 20.31–29.85 |
| Melaku et al. (2014) [ | 26.81 | 21.72–31.91 |
| Berhane et al. (2013) [ | 26.39 | 21.17–31.60 |
| Assefa et al. (2014) [ | 25.32 | 20.40–30.23 |
| Markos et al. (2019) [ | 26.02 | 20.84–31.19 |
| Meseret et al. (2015) [ | 26.49 | 21.28–31.70 |
Subgroup analysis of dual contraceptive utilization among HIV positive women in Ethiopia
| Variables | Characteristics | Included studies | Number of study participants | Prevalence (95% CI) | I2(%), |
|---|---|---|---|---|---|
| Region | Amhara | 5 | 2245 | 22.72 (16.66–28.78) | 98.3, < 0.001 |
| Oromia | 6 | 2299 | 29.96 (17.98–41.93) | 99.6, < 0.001 | |
| A. A | 1 | 1418 | 18.00 (16.32–19.63) | – | |
| Tigray | 4 | 2291 | 24.11 (11.79–36.42) | 99.5, < 0.001 | |
| Benishangul | 1 | 403 | 40.90 (38.75–43.05) | – | |
| SNNP | 2 | 512 | 24.04 (15.71–32.37) | 97.5, < 0.001 | |
| Sample size | ≤400 | 10 | 3285 | 25.58 (18.38–32.77) | 99.4, < 0.001 |
| > 400 | 9 | ,5883 | 26.77 (19.60–33.94) | 99.3, < 0.001 | |
| Year of publication | 2013–2015 | 11 | 5763 | 23.91 (19.43–28.40) | 98.5, < 0.001 |
| 2016–2018 | 2 | 639 | 20.84 (10.74–30.93) | 98.5, < 0.001 | |
| 2019–2020 | 6 | 2766 | 31.99 (18.31–45.67) | 99.7, < 0.001 | |
| Overall | 19 | 9168 | 26.14 (21.20–31.08) | 99.3, < 0.001 |
Fig. 4Association between partner involvment in post-test counseling with dual contraceptive utilization
Fig. 5Association between disclosure HIV status to partner with dual contraceptive utilization. Moreover, six primary studies also reported that open discussion on the issue dual contraceptive
Fig. 6Association between open discussion about dual contraceptive with partner and utilization of it
Fig. 7Association between provision of counseling on dual contraceptive by health care providers and utilization of it
Fig. 8Association between CD4 count with dual contraceptive utilization